PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. - Abstract - Europe PMC
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
PD-1/PD-L1 inhibitors treatment in lung cance | EurekAlert!
Mechanism of action of PD-1 and PD-L1 inhibitors. The programmed cell... | Download Scientific Diagram
Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management | RadioGraphics
Definition of immune checkpoint inhibitor - NCI Dictionary of Cancer Terms - National Cancer Institute
Frontiers | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice | Immunology
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway: Trends in Molecular Medicine
Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy - Borst - 2021 - European Journal of Immunology - Wiley Online Library
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
IJMS | Free Full-Text | Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection | HTML
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer | Oncology
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors | Cell and Developmental Biology
Revisiting the PD-1 pathway
Mechanism of action of PD-1 and PD-L1 inhibitors. The programmed cell... | Download Scientific Diagram
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer - ScienceDirect
Mechanism of action of immune checkpoint inhibitors. PD-1 is... | Download Scientific Diagram
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Ezabenlimab | Investigational Compounds | InOncology
JCI - A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therap | DDDT
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer | Full Text
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway | Abcam
